ARMISTICE CAPITAL LLC
Q3 2022 Form 13-F

NEW YORK, NEW YORK
CIK 0001601086 · CRD 168978 · SEC-registered investment adviser
$5.8B Reported Value Total

ARMISTICE CAPITAL LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $5,499,394,945, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
1 fund · $4.7B gross asset value
Hedge Fund: $4.7B
Source: Form ADV filed 2026-03-31
Reported value
$5.8B
Quarter over quarter
+0.8%
Holdings
194
Top-10 concentration
50.5%

Filing Structure

Reports holdings for

  • Armistice Capital Master Fund Ltd. (not a 13F filer in our records) · File #028-16739 · Q4 2014 – Q1 2021

Key People

Form ADV owners & control persons
Steven Joseph Boyd
MANAGING MEMBER
Jose Yldefonso Mallonga Bautista
CHIEF COMPLIANCE OFFICER AND DEPUTY CHIEF FINANCIAL OFFICER
Anthony Joseph Cordone
CHIEF FINANCIAL OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2022 13F record

Q3 2022 13F filing summary

Q3 2022 Form 13F portfolio summary
Period of report September 30, 2022
Filed November 14, 2022
Form 13F-HR
Reported value $5.8B
Positions 194
Change in reported value +0.6%
New positions 72
Exited positions 53
Position turnover 50.6%
Top-10 concentration 50.5%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
333 $8.2B
Q2 2026 13F
Filed Aug 14, 2026
323 $8.2B
Q1 2026 13F
Filed May 15, 2026
251 $5.6B
Q4 2025 13F
Filed Feb 17, 2026
357 $8.4B
Q3 2025 13F
Filed Nov 17, 2025
318 $6.7B
Q2 2025 13F
Filed Aug 14, 2025
200 $5.8B
Q1 2025 13F
Filed May 15, 2025
220 $6.7B
Q4 2024 13F
Filed Feb 14, 2025
227 $7.3B
Q3 2024 13F
Filed Nov 14, 2024
254 $6.3B
Q2 2024 13F
Filed Aug 14, 2024
250 $7.9B
Q1 2024 13F
Filed May 15, 2024
333 $7.5B
Q4 2023 13F
Filed Feb 13, 2024
290 $7.3B
Q3 2023 13F
Filed Nov 14, 2023
250 $6.5B
Q2 2023 13F
Filed Aug 14, 2023
218 $6.9B
Q1 2023 13F
Filed May 15, 2023
223 $6.9B
Q4 2022 13F
Filed Feb 14, 2023
191 $5.7B
Q3 2022 13F
Filed Nov 14, 2022
194 $5.8B
Q2 2022 13F
Filed Aug 15, 2022
175 $5.7B
Q1 2022 13F
Filed May 16, 2022
139 $5.2B
Q4 2021 13F
Filed Feb 14, 2022
143 $6.1B

28 earlier quarters on file — choose one from the quarter menu above.

Top 20 holdings · Q3 2022

Largest Q3 2022 13F positions by reported value
# Holding Reported value % of portfolio
1 SPY P SPDR S&P 500 ETF TR $1.2B 20.76%
2 IWM P ISHARES TR $593.7M 10.3%
3 INCY INCYTE CORP $157.7M 2.73%
4 SUPN SUPERNUS PHARMACEUTICALS INC $155.5M 2.7%
5 PTCT PTC THERAPEUTICS INC $145.6M 2.53%
6 TVTX TRAVERE THERAPEUTICS INC $143.8M 2.49%
7 NBIX NEUROCRINE BIOSCIENCES INC $140.6M 2.44%
8 FRPT FRESHPET INC $137.0M 2.38%
9 MRTX MIRATI THERAPEUTICS INC $132.7M 2.3%
10 ENTA ENANTA PHARMACEUTICALS INC $107.5M 1.86%
11 GSK GSK PLC $105.9M 1.84%
12 ROST ROSS STORES INC $97.6M 1.69%
13 REGN REGENERON PHARMACEUTICALS $93.7M 1.63%
14 DCPH DECIPHERA PHARMACEUTICALS IN $88.2M 1.53%
15 PCRX PACIRA BIOSCIENCES INC $84.7M 1.47%
16 ALKS ALKERMES PLC $84.7M 1.47%
17 MDGL MADRIGAL PHARMACEUTICALS INC $80.3M 1.39%
18 FIVE FIVE BELOW INC $76.2M 1.32%
19 LULU LULULEMON ATHLETICA INC $73.1M 1.27%
20 ORLY OREILLY AUTOMOTIVE INC $70.5M 1.22%

Values as reported on the Q3 2022 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings